» Articles » PMID: 38068367

Echocardiography and Electrocardiography in Detecting Atrial Cardiomyopathy: A Promising Path to Predicting Cardioembolic Strokes and Atrial Fibrillation

Abstract

(1) Background: Atrial cardiomyopathy constitutes an intrinsically prothrombotic atrial substrate that may promote atrial fibrillation and thromboembolic events, especially stroke, independently of the arrhythmia. Atrial reservoir strain is the echocardiography marker with the most robust evidence supporting its prognostic utility. The main aim of this study is to identify atrial cardiomyopathy by investigating the association between left atrial dysfunction in echocardiography and P-wave abnormalities in the surface electrocardiogram. (2) Methods: This is a community-based, multicenter, prospective cohort study. A randomized sample of 100 patients at a high risk of developing atrial fibrillation were evaluated using diverse echocardiography imaging techniques, and a standard electrocardiogram. (3) Results: Significant left atrial dysfunction, expressed by a left atrial reservoir strain < 26%, showed a relationship with the dilation of the left atrium ( < 0.001), the left atrial ejection fraction < 50% ( < 0.001), the presence of advanced interatrial block ( = 0.032), P-wave voltage in lead I < 0.1 mV ( = 0.008), and MVP ECG score ( = 0.036). (4) Conclusions: A significant relationship was observed between left atrial dysfunction and the presence of left atrial enlargement and other electrocardiography markers; all of them are non-invasive biomarkers of atrial cardiomyopathy.

Citing Articles

Evidence Gaps and Lessons in the Early Detection of Atrial Fibrillation: A Prospective Study in a Primary Care Setting (PREFATE Study).

Clua-Espuny J, Hernandez-Pinilla A, Gentille-Lorente D, Muria-Subirats E, Forcadell-Arenas T, de Diego-Cabanes C Biomedicines. 2025; 13(1).

PMID: 39857703 PMC: 11759169. DOI: 10.3390/biomedicines13010119.


[MVP Risk score and new atrial fibrillation diagnosis: Prospective cohort PREFATE study].

Clua-Espuny J, Gentille-Lorente D, Hernandez-Pinilla A, Satue-Gracia E, Palleja-Millan M, Martin-Lujan F Aten Primaria. 2024; 57(1):103071.

PMID: 39265318 PMC: 11415850. DOI: 10.1016/j.aprim.2024.103071.

References
1.
Healey J, Lopes R, Granger C, Alings M, Rivard L, McIntyre W . Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. N Engl J Med. 2023; 390(2):107-117. DOI: 10.1056/NEJMoa2310234. View

2.
Maheshwari A, Norby F, Inciardi R, Wang W, Zhang M, Soliman E . Left Atrial Mechanical Dysfunction and the Risk for Ischemic Stroke in People Without Prevalent Atrial Fibrillation or Stroke : A Prospective Cohort Study. Ann Intern Med. 2022; 176(1):39-48. PMC: 11793084. DOI: 10.7326/M22-1638. View

3.
Pala E, Bustamante A, Clua-Espuny J, Acosta J, Gonzalez-Loyola F, Santos S . Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study. PLoS One. 2022; 17(8):e0273571. PMC: 9398023. DOI: 10.1371/journal.pone.0273571. View

4.
Pagola J, Gonzalez-Alujas T, Flores A, Muchada M, Rodriguez-Luna D, Sero L . Left atria strain is a surrogate marker for detection of atrial fibrillation in cryptogenic strokes. Stroke. 2014; 45(8):e164-6. DOI: 10.1161/STROKEAHA.114.005540. View

5.
Nassri Camara E, do Prado Valladares F, Key N, Santana P, Kawaoka J, Campos T . Indexing of Left Atrial Volume by Body Surface Area and Height in a Brazilian Population without Previous Heart Disease and with a Normal Heart on Echocardiography. Behavior in Obese and Overweight Patients. Cardiol Cardiovasc Med. 2023; 7(1):25-31. PMC: 10019596. DOI: 10.26502/fccm.92920304. View